U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H44N4O6
Molecular Weight 508.6518
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of RIBAVIRIN ELAIDATE

SMILES

CCCCCCCC/C(/[H])=C(\[H])/CCCCCCCC(=O)OC[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(n2cnc(C(=O)N)n2)O1)O)O

InChI

InChIKey=HNJWVTLAOZFLEK-OOWZQQDUSA-N
InChI=1S/C26H44N4O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(31)35-18-20-22(32)23(33)26(36-20)30-19-28-25(29-30)24(27)34/h9-10,19-20,22-23,26,32-33H,2-8,11-18H2,1H3,(H2,27,34)/b10-9+/t20-,22-,23-,26-/m1/s1

HIDE SMILES / InChI
Ribavirin elaidate (CP-4033; TRX-201), a Lipid Vector Technology derivative of ribavirin. It inhibits elongation factor F4E (elF4E), which stimulates cell growth. Translational Therapeutics Inc. received orphan drug status from the U.S. Food and Drug Administration (FDA) in 2011 for ribavirin elaidate in the treatment of aggressive follicular, medullary and anaplastic thyroid carcinoma.

Approval Year

Name Type Language
RIBAVIRIN ELAIDATE
Common Name English
RIBAVIRIN-5'-ELAIDIC ACID ESTER
Common Name English
1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE, 1-(5-O-((9E)-1-OXO-9-OCTADECEN-1-YL)-.BETA.-D-RIBOFURANOSYL)-
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 344011
Created by admin on Sat Jun 26 11:48:20 UTC 2021 , Edited by admin on Sat Jun 26 11:48:20 UTC 2021
Code System Code Type Description
CAS
1352921-29-9
Created by admin on Sat Jun 26 11:48:20 UTC 2021 , Edited by admin on Sat Jun 26 11:48:20 UTC 2021
PRIMARY
EPA CompTox
1352921-29-9
Created by admin on Sat Jun 26 11:48:20 UTC 2021 , Edited by admin on Sat Jun 26 11:48:20 UTC 2021
PRIMARY
FDA UNII
4LU13X0I13
Created by admin on Sat Jun 26 11:48:20 UTC 2021 , Edited by admin on Sat Jun 26 11:48:20 UTC 2021
PRIMARY
PUBCHEM
49848291
Created by admin on Sat Jun 26 11:48:20 UTC 2021 , Edited by admin on Sat Jun 26 11:48:20 UTC 2021
PRIMARY